Ibrutinib
B-Cell Chronic Lymphocytic Leukemia
Janssen Research & Development, LLCSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 81/ 100
Competitive context
66 Active assets in the B-Cell Chronic Lymphocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Humax-Cd20 Emory University | Phase 4 | BBB |
Acalabrutinib Zulfa Omer | Phase 4 | BBB |
Fludarabine Ohio State University Comprehensive Cancer Center | Phase 4 | BBB |
Rituximab Zulfa Omer | Phase 4 | BBB |
Cyclophosphamide Ohio State University Comprehensive Cancer Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Ibrutinib is also rated in:
chronic lymphocytic leukemia/small lymphocytic lymphomaActive
BB
Indicative · Phase 3
68 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →